A recent article published in JAMA found that of 49 top brand-name prescription drugs in the U.S., 78 percent of them have posted a more than 50 percent increase in insurer and out of pocket costs since 2012.
According to the article, 44 percent of those drugs doubled in price.
The researchers found “substantial cost increases among these drugs was near universal.”
“The growth of drug spending in the United States associated with government-protected market exclusivity is likely to continue; greater price transparency is warranted,” the authors write.
